<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346008</url>
  </required_header>
  <id_info>
    <org_study_id>NBCI-03-033-CM</org_study_id>
    <secondary_id>NCI-06-C-N026</secondary_id>
    <secondary_id>CDR0000551606</secondary_id>
    <secondary_id>NBCI-01-087-CM</secondary_id>
    <secondary_id>999906026</secondary_id>
    <nct_id>NCT00346008</nct_id>
    <nct_alias>NCT00482534</nct_alias>
  </id_info>
  <brief_title>Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members</brief_title>
  <official_title>Genetic Epidemiologic Studies of Melanoma in Iceland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iceland Genomics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and
      their family members may help doctors identify biomarkers related to cancer.

      PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland
      and their family members.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in
           multiple-case families, individuals with multiple tumors, and selected additional family
           members in Iceland.

        -  Assess the feasibility of mutation detection using sequencing and HPLC.

        -  Determine UVS' ability to create datasets with demographic, epidemiologic and molecular
           data.

      OUTLINE: Participants and patients undergo blood collection and complete lifestyle
      questionnaires. All patients and population-based controls have DNA samples sequenced for
      MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing
      of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Feasibility to identify melanoma</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility to detect mutation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability to create datasets</measure>
  </primary_outcome>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Patients diagnosed with melanoma and selected family members are eligible to
             participate

          -  Must live in Iceland

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alisa Goldstein, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iceland Genomics Corporation</name>
      <address>
        <city>Reykjavik</city>
        <zip>105</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iceland</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage I melanoma</keyword>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

